.jpeg)
2026-09-20 03:07:09
Ramosetron Hydrochloride orally disintegrating tablets are selective 5-HT3 receptor antagonists that act on gastrointestinal neural signaling pathways. Approved indications vary by region; in Japan, ramosetron is approved for adults with diarrhea-predominant irritable bowel syndrome, but it is not approved for this indication in every country or region.
2026-09-18 05:26:29
Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist for adults with type 2 diabetes–related chronic kidney disease and for heart failure with LVEF≥40%. Start by eGFR, titrate by serum potassium, monitor UACR, renal function, and hyperkalemia risk.
2026-09-17 03:13:54
Baxdrostat is an oral aldosterone synthase inhibitor for adults with hypertension inadequately controlled on other antihypertensives. Usual dose 2mg once daily, 1mg if hyperkalemia/hyponatremia risk; monitor potassium, sodium, and blood pressure, do not self-stop.
2026-09-17 03:06:52
Pixclara is Telix’s F-18 amino-acid PET agent for adults and children aged 1 month and older, used with PET to help differentiate recurrent or progressive glioma from treatment-related brain changes. Interpret alongside MRI, history, and clinical findings rather than as stand-alone proof.
2026-09-17 02:55:47
Adagrasib is an oral irreversible KRAS G12C inhibitor. NSCLC standard dosing is 600mg twice daily; manage diarrhea, nausea, hepatotoxicity, QTc prolongation, and ILD. Colorectal use with cetuximab is under re-evaluation after KRYSTAL-10 missed PFS/OS endpoints.
2026-09-17 02:41:20
Bexlutry is Curium’s lutetium-177 octreotate radioligand for adults with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors. Standard regimen is 7.4GBq IV every 8 weeks for 4 cycles with amino-acid renal protection; monitor marrow, kidney, liver, and carcinoid crisis.
2026-09-16 05:46:05
Etrasimod is an oral S1P1/4/5 modulator for moderately to severely active ulcerative colitis. Usual dosing is 2mg once daily without titration; some patients improve by 2 weeks and are assessed for remission at 12 weeks, with ECG, LFT, CBC, and ophthalmology monitoring.
2026-09-15 07:32:36
Hibsago (bepirovirsen), an GSK/Ionis antisense oligonucleotide, was approved in Japan for adult chronic hepatitis B functional cure. This page covers its ASO mechanism, 6-month subcutaneous regimen, pooled B-Well 1/2 functional cure rates, and safety notes on injection-site reactions and transaminases.
2026-09-15 07:24:01
In September 2026, the FDA approved Scholar Rock’s Isembyld (apitegromab-mstn) for Spinal Muscular Atrophy (SMA). As the first therapy targeting skeletal muscle, it offers a novel combination approach alongside SMN2-directed therapies for patients aged 2 and older.
2026-09-14 03:57:21
Progression on enzalutamide does not mean no options. mCRPC follow-up uses HRR/BRCA testing for PARP inhibitors, PSMA PET for lutetium-177, and chemotherapy history plus bone/visceral disease for docetaxel or cabazitaxel.
2026-09-14 03:36:10
Ceritinib is an oral ALK tyrosine kinase inhibitor for validated ALK-rearranged locally advanced or metastatic non-small cell lung cancer. Usual 450mg once daily with food, with active management of diarrhea, hepatotoxicity, hyperglycemia, and QT prolongation.
2026-09-14 03:29:24
Acalabrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma is assessed by age, stage, TP53/17p status, prior therapy, and relapse. Long-term data support progression-free survival and durable disease control rather than a fixed “added years” estimate.
